FerGene Gene Therapy Nadofaragene Firadenovec Phase 3 Clinical Trial Reaches Major Clinical End

recently, Genetherapycompany(http://FerGene announced that gene therapy nadofaragene firadenovec (rAd-IFN/Syn3) has reached a major clinical end point in the clinicaltrial(http://for patients with advanced advanced advanced non-muscular leachate bladder cancer (http:// who have poorly responded to BCGWith regard to Nadofaragene firadenovec
Nadofaragene firadenovec was originally developed by Finnish gene therapy company FKD Therapies Oy, Ferring Pharmaceuticals in 2018 in partnership with FKD Therapies Oy to develop this gene therapy and transferred the asset to Fer GeneNadofaragene firadenovec is a gene therapy based on adenovirus vectors that require sending adenovirus vectors containing interferon alpha-2b transgenic to the bladder every 3 months by ductizationWhen entering the bladder wall cells, by transfection of the bladder endothelial cells, resulting in the bladder producing a large amount of interferon alpha-2b protein, which in turn enhances its anti-tumor activityThis new gene therapy mechanism transforms a patient's own bladder wall cells into a microfactory that makes a variety of interferons, enhancing the body's natural defenses against cancerIn Phase 3 clinical trials involving 157 patients, 53% of patients with insitual cancer (with or without advanced Ta or T1 papilloma), who achieved complete remission (CR) after 3 months of treatment, and 24% of patients who achieved full remission after 12 months of treatmentIn addition, 73% of patients with advanced Ta/T1 papilloma, who achieved no advanced relapse survival (high grade-grade-recurrence-free, HGRF) after 3 months of treatment, were 44% hgRF survival after 12 months of treatment